cyanocob(III)alaminWhat was measured
Measured, with no finding
3,745 endpoints
Show what was measuredHide what was measured
change in blood hemoglobin at 3 months, vitamin B12 treatment group versus placebo group (also plasma methylmalonic acid, plasma total homocysteine, mean cell volume, symptom scores, Neurological Disability Score)
no effect, p = 0.18
Not recorded as a finding: the supporting sentence never names the compound
P-MMA (P <0.001) or plasma total homocysteine (P <0.001) decreased in the treatment group vs the placebo group, but no significant difference was found in the change of blood hemoglobin (P = 0.18) and mean cell volume (P = 0.71).
PMID 11468228 · one of two readings recorded this
change in blood hemoglobin, treatment group versus placebo, 3 months
no effect, no significant difference in change of blood hemoglobin, p = 0.18
Not recorded as a finding: the supporting sentence never names the compound
P-MMA (P <0.001) or plasma total homocysteine (P <0.001) decreased in the treatment group vs the placebo group, but no significant difference was found in the change of blood hemoglobin (P = 0.18) and mean cell volume (P = 0.71).
PMID 11468228 · one of two readings recorded this
change in blood hemoglobin
no effect, p = 0.18
no significant difference was found in the change of blood hemoglobin (P = 0.18)
PMID 11468228 · one of two readings recorded this
change in mean cell volume
no effect, p = 0.71
and mean cell volume (P = 0.71)
PMID 11468228 · one of two readings recorded this
change in Neurological Disability Score
no effect, p = 0.85
or the Neurological Disability Score (P = 0.85)
PMID 11468228 · one of two readings recorded this
change in symptom score, gastroenterologic symptoms
no effect, p = 0.32
gastroenterologic symptoms (P = 0.32)
PMID 11468228 · one of two readings recorded this
change in symptom score, neurologic symptoms
no effect, p = 0.21
neurologic symptoms (P = 0.21)
PMID 11468228 · one of two readings recorded this
change in symptom score, symptoms of anemia
no effect, p = 0.63
Changes in symptom scores did not differ between the groups for symptoms of anemia (P = 0.63)
PMID 11468228 · one of two readings recorded this
plasma methylmalonic acid (P-MMA)
decreases, p = 0.001
P-MMA (P <0.001) or plasma total homocysteine (P <0.001) decreased in the treatment group vs the placebo group
PMID 11468228 · one of two readings recorded this
plasma total homocysteine
decreases, p = 0.001
P-MMA (P <0.001) or plasma total homocysteine (P <0.001) decreased in the treatment group vs the placebo group
PMID 11468228 · one of two readings recorded this
disability
decreases, p = 0.0002
However, comparison between groups at the end of the treatment period showed a statistically significant difference in favour of the active treatment both for VAS and DQ (p < 0.0001 and p < 0.0002, respectively)
PMID 11558625 · one of two readings recorded this
low back pain intensity on a visual analogic scale (VAS) and Disability Questionnaire, intramuscular vitamin B12
between-group difference in favour of active treatment for VAS and DQ
Not recorded as a finding: the direction is carried only as a signed number
However, comparison between groups at the end of the treatment period showed a statistically significant difference in favour of the active treatment both for VAS and DQ (p < 0.0001 and p < 0.0002, respectively).
PMID 11558625 · one of two readings recorded this
pain and disability
decreases
Both treatment groups experienced a sharp decrease in pain and disability
PMID 11558625 · one of two readings recorded this
pain intensity
decreases, p = 0.0001
However, comparison between groups at the end of the treatment period showed a statistically significant difference in favour of the active treatment both for VAS and DQ (p < 0.0001 and p < 0.0002, respectively)
PMID 11558625 · one of two readings recorded this
paracetamol consumption
decreases, p = 0.0001
Consumption of paracetamol proved significantly higher in the placebo group than in the active treatment (p < 0.0001)
PMID 11558625 · one of two readings recorded this
health-related quality of life
decreases, p = 0.001
The participants reported a significantly worser HRQOL than the age- and sex-matched Danish general population (P < 0.001)
PMID 12542554 · one of two readings recorded this
general health dimension
increases, p = 0.03
A significant improvement was found only in general health when compared with the placebo group (P = 0.03)
PMID 12542554 · one of two readings recorded this
health-related quality of life by the SF-36 questionnaire, reported per health dimension (eight dimensions), change from baseline to 3 months after weekly vitamin B-12 injections versus placebo
increases, p = 0.03
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
A significant improvement was found only in general health when compared with the placebo group (P = 0.03).
PMID 12542554 · one of two readings recorded this
seven of eight SF-36 health dimensions
no effect
no change was observed after treatment with vitamin B-12 for seven of eight health dimensions
PMID 12542554 · one of two readings recorded this
SF-36 health-related quality of life, general health dimension, change over 3 months
increases, significant improvement in general health versus placebo, p = 0.03
Not recorded as a finding: a node exists but the paper states a different instrument or population
A significant improvement was found only in general health when compared with the placebo group (P = 0.03).
PMID 12542554 · one of two readings recorded this
cognitive function in people with dementia and low serum vitamin B12, instrument not stated
no effect
Not recorded as a finding: the paper never states the instrument the node requires
From the two included studies (Seal 2002; Fourniere 1997) of people with dementia and low serum vitamin B12 levels, there was no statistically significant evidence of treatment effect, vitamin B12 supplementation compared with placebo, on cognitive function.
PMID 12918012 · one of two readings recorded this
cognitive function
no effect
there was no statistically significant evidence of treatment effect, vitamin B12 supplementation compared with placebo, on cognitive function
PMID 12918012 · one of two readings recorded this
change in serum cobalamin concentration across time
increases, p = 0.0001
The increase in each group across time was statistically significant (P = 0.0001, differences [95% confidence intervals] 194.2 (114.5, 273.9), 178.3 (104.2, 252.4), and 195.1 (135.0, 255.2) pmol l-1, respectively)
PMID 14616423 · one of two readings recorded this
change in serum cobalamin concentration across time
increases, p = 0.0001
The increase in each group across time was statistically significant (P = 0.0001, differences [95% confidence intervals] 194.2 (114.5, 273.9), 178.3 (104.2, 252.4), and 195.1 (135.0, 255.2) pmol l-1, respectively)
PMID 14616423 · one of two readings recorded this
change in serum cobalamin concentration across time
increases, p = 0.0001
The increase in each group across time was statistically significant (P = 0.0001, differences [95% confidence intervals] 194.2 (114.5, 273.9), 178.3 (104.2, 252.4), and 195.1 (135.0, 255.2) pmol l-1, respectively)
PMID 14616423 · one of two readings recorded this
serum cobalamin concentration after 4 weeks of sublingual or oral cobalamin 500 ug daily versus oral vitamin B complex
no effect
Not recorded as a finding: this platform holds no node for the endpoint
There was no significant difference in concentrations between the treatment groups.
PMID 14616423 · one of two readings recorded this
serum cobalamin concentration after 4 weeks, sublingual 500 ug cobalamin versus oral 500 ug cobalamin versus oral vitamin B complex
no effect
Not recorded as a finding: the comparison was against another active treatment
There was no significant difference in concentrations between the treatment groups.
PMID 14616423 · one of two readings recorded this
serum cobalamin concentration after 4 weeks, sublingual versus oral 500 ug cobalamin versus oral B-complex
no effect
Not recorded as a finding: the comparison was against another active treatment
There was no significant difference in concentrations between the treatment groups.
PMID 14616423 · one of two readings recorded this
serum cobalamin concentration (pmol/l) after 4 weeks of sublingual versus oral cobalamin 500 ug versus oral B-complex
no effect
Not recorded as a finding: this platform holds no node for the endpoint
There was no significant difference in concentrations between the treatment groups.
PMID 14616423 · one of two readings recorded this
serum cobalamin concentration
n = 30
Serum cobalamin concentrations before treatment were 94 +/- 30 pmol l-1, 108 +/- 17 pmol l-1 and 98 +/- 14 pmol l-1 in the sublingual B12, oral B12 and oral B-complex groups, respectively
PMID 14616423 · one of two readings recorded this
serum cobalamin concentration
no effect, n = 30
After 4 weeks, concentrations rose to 288 +/- 74 pmol l-1, 286 +/- 87 pmol l-1 and 293 +/- 78 pmol l-1, respectively
PMID 14616423 · one of two readings recorded this
hearing thresholds and TTS2 in control group after 8 days
no effect
After 8 days of treatment, the control group showed the same hearing thresholds and TTS2 degrees
PMID 15198380 · one of two readings recorded this
noise-induced temporary threshold shift (TTS2) at 3 and 4 kHz
decreases
TTS2 decreased significantly at 3 and 4kHz when cobalamin was used to increase the serum concentration of vitamin B12 to > 2350 pg/ml
PMID 15198380 · one of two readings recorded this
noise-induced temporary threshold shift (TTS2) at 3 kHz
decreases
a protective effect at 3 kHz in the experimental group was evident when compared with the placebo group
PMID 15198380 · one of two readings recorded this
serum vitamin B12 concentration
increases
At the end of treatment, the serum vitamin B12 concentration was significantly increased in the experimental group
PMID 15198380 · one of two readings recorded this
change in cognitive function by total CAMCOG score (Cambridge Cognitive Examination), and depression score on the Major Depression Inventory, baseline to 3 months; MMSE and a 12-words learning test were also administered but no MMSE result is stated
total CAMCOG score, P = 0.43, p = 0.43
Not recorded as a finding: this platform holds no node for the endpoint
No improvement was found in cognitive function comparing the treatment and placebo group (total CAMCOG score: P = 0.43), nor among individuals with only slightly impaired cognitive function (n = 44, total CAMCOG score: P = 0.42).
PMID 15337331 · one of two readings recorded this
change in depression score
no effect, p = 0.18
The treatment group did not improve in depression score as compared to the placebo group (P = 0.18)
PMID 15337331 · one of two readings recorded this
change in total CAMCOG score
no effect, p = 0.43
No improvement was found in cognitive function comparing the treatment and placebo group (total CAMCOG score: P = 0.43)
PMID 15337331 · one of two readings recorded this
change in total CAMCOG score
no effect, p = 0.42, n = 44
nor among individuals with only slightly impaired cognitive function (n = 44, total CAMCOG score: P = 0.42)
PMID 15337331 · one of two readings recorded this
prevalence of cognitive impairment at baseline by CAMCOG
At baseline 78 (56%) individuals had cognitive impairment judged from the CAMCOG score and 40 (29%) according to the MMSE; 18 (13%) individuals had symptoms of depression.
PMID 15337331 · one of two readings recorded this
prevalence of cognitive impairment at baseline by MMSE
At baseline 78 (56%) individuals had cognitive impairment judged from the CAMCOG score and 40 (29%) according to the MMSE; 18 (13%) individuals had symptoms of depression.
PMID 15337331 · one of two readings recorded this
prevalence of symptoms of depression at baseline
At baseline 78 (56%) individuals had cognitive impairment judged from the CAMCOG score and 40 (29%) according to the MMSE; 18 (13%) individuals had symptoms of depression.
PMID 15337331 · one of two readings recorded this
total CAMCOG score (Cambridge Cognitive Examination), change from baseline to 3 months; also Major Depression Inventory score
p = 0.43
Not recorded as a finding: this platform holds no node for the endpoint
No improvement was found in cognitive function comparing the treatment and placebo group (total CAMCOG score: P = 0.43), nor among individuals with only slightly impaired cognitive function (n = 44, total CAMCOG score: P = 0.42).
PMID 15337331 · one of two readings recorded this
autonomic symptoms
decreases
In three studies, methylcobalamin therapy improved autonomic symptoms
PMID 16008162 · one of two readings recorded this
somatic symptoms (pain and paresthesia)
decreases
Both the vitamin B12 combination and pure methylcobalamin had beneficial effects on somatic symptoms, such as pain and paresthesia
PMID 16008162 · one of two readings recorded this
vibration perception and electrophysiological measures
unclear
Effects on vibration perception and electrophysiological measures were not consistent
PMID 16008162 · one of two readings recorded this
fraction of pemetrexed excreted unchanged in urine
The Fe averaged 0.752 (range, 0.645–0.827)
PMID 16940981 · one of two readings recorded this
maximum tolerated dose of pemetrexed with FA/VB12
n = 6
As two DLTs were observed, the 1200 mg m−2 dose level was considered as the MTD
PMID 16940981 · one of two readings recorded this
mean elimination half-life of pemetrexed
no effect
The overall mean t1/2 is approximately 2.74 h and was essentially similar across all dose groups (range, 2.28–3.62 h)
PMID 16940981 · one of two readings recorded this
partial response
n = 23
Partial responses (PRs) were observed in four patients with NSCLC (one patient each at 500, 700, 800, and 1200 mg m−2) and one patient with thymoma at 500 mg m−2
PMID 16940981 · one of two readings recorded this
patients evaluable for tumour response
n = 23
In this study, 23 of the 31 patients were evaluable for response by RECIST criteria
PMID 16940981 · one of two readings recorded this
patients with rash in cycle 1
n = 25
At cycle 1, 25 patients experienced rash
PMID 16940981 · one of two readings recorded this
recommended dose of pemetrexed with FA/VB12
The RD for subsequent phase II studies was then evaluated to be pemetrexed 1000 mg m−2
PMID 16940981 · one of two readings recorded this
duration of outbreaks
decreases, p = 0.05
The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood
PMID 19124628 · one of two readings recorded this
duration of outbreaks
decreases, p = 0.05
The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood
PMID 19124628 · one of two readings recorded this
level of pain in recurrent aphthous stomatitis at 5 and 6 months of sublingual vitamin B12; also outbreak duration and number of ulcers
decreases
Not recorded as a finding: the paper never states the instrument the node requires
The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood.
PMID 19124628 · one of two readings recorded this
level of pain in recurrent aphthous stomatitis, instrument not named in the abstract
decreases, reduced at 5 and 6 months of treatment
Not recorded as a finding: the paper never states the instrument the node requires
The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood.
PMID 19124628 · one of two readings recorded this
level of pain
decreases, p = 0.05
The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood
PMID 19124628 · one of two readings recorded this
level of pain
decreases, p = 0.05
The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood
PMID 19124628 · one of two readings recorded this
number of ulcers
decreases, p = 0.05
The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood
PMID 19124628 · one of two readings recorded this
number of ulcers
decreases, p = 0.05
The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood
PMID 19124628 · one of two readings recorded this
participants reaching no aphthous ulcers status
During the last month of treatment a significant number of participants in the intervention group reached "no aphthous ulcers status" (74.1% vs 32.0%; P < .01)
PMID 19124628 · one of two readings recorded this
participants reaching no aphthous ulcers status
increases, p = 0.01
During the last month of treatment a significant number of participants in the intervention group reached "no aphthous ulcers status" (74.1% vs 32.0%; P < .01)
PMID 19124628 · one of two readings recorded this
pain score on a visual analogue scale in painful diabetic neuropathy, parenteral vitamin B12 versus nortriptyline
decreases, decrease of 3.66 units versus 0.84 units
Not recorded as a finding: the comparison was against another active treatment
After treatment, the pain score based on a visual analogue scale decreased 3.66 units in the vitamin B(12) group and 0.84 units in the nortriptyline group (P <0.001).
PMID 19212856 · both readings recorded this
pain score
decreases, p = 0.001
the pain score based on a visual analogue scale decreased 3.66 units in the vitamin B(12) group and 0.84 units in the nortriptyline group (P <0.001)
PMID 19212856 · one of two readings recorded this
paresthesia score
decreases, p = 0.001
the paresthesia score decreased 2.98 units versus 1.06 units (P <0.001)
PMID 19212856 · one of two readings recorded this
tingling sensation
decreases, p = 0.001
The decrements of tingling sensation were 3.48 units versus 1.02 units (P <0.001)
PMID 19212856 · one of two readings recorded this
vibration, position, pinprick and nerve conduction parameters
no effect
Changes in vibration, position, pinprick and nerve conduction parameters were not significant in two groups
PMID 19212856 · one of two readings recorded this
B12 deficiency at baseline
At baseline 48% participants were B12 deficient
PMID 20216560 · one of two readings recorded this
baseline-adjusted change in plasma tHcy
no effect
The B0 group showed a non-significant rise of 1.2 (95% CI: −0.5, 2.8) μmol/L
PMID 20216560 · one of two readings recorded this
baseline-adjusted change in plasma tHcy
decreases
7.1 (95% CI: −8.9, −5.4) μmol/L in the B10 group
PMID 20216560 · one of two readings recorded this
baseline-adjusted change in plasma tHcy
decreases
The baseline-adjusted fall was 5.9 (95% CI: −7.8, −4.1) μmol/L in the B2 group
PMID 20216560 · one of two readings recorded this
change in plasma tHcy
decreases
F0 2.8 (95% CI: −4.3, −1.2) μmol/L
PMID 20216560 · one of two readings recorded this
change in plasma tHcy
decreases
F200 4.8 (95% CI: −6.3, −3.3) μmol/L
PMID 20216560 · one of two readings recorded this
interaction between B12 and folic acid on change in plasma tHcy
no effect, p = 0.14
There was no significant interaction between the effects of B12 and folic acid supplementation on change in plasma tHcy concentration (P=0.14
PMID 20216560 · one of two readings recorded this
number needed to treat for hyperhomocysteinemia
The number needed to treat (NNT) was 4 for B2, 2 for B10 and 10 for F200 group
PMID 20216560 · one of two readings recorded this
number needed to treat for hyperhomocysteinemia
The number needed to treat (NNT) was 4 for B2, 2 for B10 and 10 for F200 group
PMID 20216560 · one of two readings recorded this
number needed to treat for hyperhomocysteinemia
The number needed to treat (NNT) was 4 for B2, 2 for B10 and 10 for F200 group
PMID 20216560 · one of two readings recorded this
plasma total homocysteine (tHcy), fluorescence polarization immunoassay; plasma vitamin B12 and folate, microbiological assay
decreases
Not recorded as a finding: this platform holds no node for the endpoint
The baseline-adjusted fall was 5.9 (95% CI: −7.8, −4.1) μmol/L in the B2 group and 7.1 (95% CI: −8.9, −5.4) μmol/L in the B10 group (not significantly different).
PMID 20216560 · one of two readings recorded this
plasma vitamin B12 concentration, microbiological assay (L. leichmanii)
increases
Not recorded as a finding: the only sentence naming the rise is a within-arm statement and the no-B12 arm also rose 33% above baseline, so no between-arm contrast sentence exists
Plasma B12 concentrations increased significantly in those who received B12 supplements.
PMID 20216560 · both readings recorded this
proportion hyperhomocysteinemic
increases, p = 0.02
in the B0 group it increased from 44% to 56% (P=0.02)
PMID 20216560 · one of two readings recorded this
proportion hyperhomocysteinemic
decreases
in the B10 group from 56% to 21% (P<0.000)
PMID 20216560 · one of two readings recorded this
proportion hyperhomocysteinemic
decreases, p = 0.02
in the B2 group the proportion of hyperhomocysteinemic participants fell from 52% to 39% (P=0.02)
PMID 20216560 · one of two readings recorded this
proportion hyperhomocysteinemic
no effect, p = 0.07
In the F0 group the proportion of hyperhomocysteinemic participants fell from 53% to 44%, P=0.07
PMID 20216560 · one of two readings recorded this
proportion hyperhomocysteinemic
decreases, p = 0.003
in the F200 group from 48% to 34%, P=0.003
PMID 20216560 · one of two readings recorded this
remaining B12 deficiency after supplementation (B10)
After 12 mo of supplementation 6% of the B2 and 2% of the B10 group remained B12 deficient
PMID 20216560 · one of two readings recorded this
remaining B12 deficiency after supplementation (B2)
After 12 mo of supplementation 6% of the B2 and 2% of the B10 group remained B12 deficient
PMID 20216560 · one of two readings recorded this
rise in plasma folate from baseline
increases
increased by 112% in those who received folic acid (F200) and by 18.8% in the group who did not (F0)
PMID 20216560 · one of two readings recorded this
rise in plasma folate from baseline
increases
Plasma folate concentrations increased by 112% in those who received folic acid (F200)
PMID 20216560 · one of two readings recorded this
rise in plasma vitamin B12 from baseline
increases
Participants who did not receive B12 (B0) also showed a rise in plasma B12 concentration (33% above baseline) after 12 mo
PMID 20216560 · one of two readings recorded this
rise in plasma vitamin B12 from baseline
increases
119% in those who received 10 μg (B10)
PMID 20216560 · one of two readings recorded this
rise in plasma vitamin B12 from baseline
increases
At 12 mo the rise was 64% in those who received 2 μg (B2)
PMID 20216560 · one of two readings recorded this
Prostate cancer risk, highest versus lowest quartile of holo-haptocorrin
increases, p = 0.01
highest versus lowest quartile of holo-haptocorrin OR = 1.27 (1.04-1.56); P(trend) = 0.01
PMID 20501771 · one of two readings recorded this
Prostate cancer risk, highest versus lowest quartile of plasma vitamin B12
increases, p = 0.06
highest versus lowest quartile of B(12) odds ratio (OR) = 1.17 (95% confidence interval, 0.95-1.43); P(trend) = 0.06
PMID 20501771 · one of two readings recorded this
Prostate cancer risk, pooled meta-analysis, per 10 nmol/L increase in circulating folate
increases, p = 0.02
OR = 1.18 (1.00-1.40) per 10 nmol/L; P = 0.02
PMID 20501771 · one of two readings recorded this
Prostate cancer risk, pooled meta-analysis, per 10 nmol/L increase in circulating folate
no effect, p = 0.2
OR = 1.11 (0.96-1.28) per 10 nmol/L; P = 0.2
PMID 20501771 · one of two readings recorded this
Prostate cancer risk, pooled meta-analysis, per 100 pmol/L increase in circulating B12
increases, p = 0.002
pooled OR = 1.10 (1.01-1.19) per 100 pmol/L increase in B(12); P = 0.002
PMID 20501771 · one of two readings recorded this
adherence, proportion of days with correct medication
no effect
Doses and proportion of days with correct medication were 27.4 intakes and 93.5% of days for the oral B12 group and 28.4 intakes and 94.4% of days for the placebo group
PMID 21232119 · one of two readings recorded this
baseline serum homocysteine
n = 50
Mean (SD) | 18.3 μmol/l (SD = 6.6)* | 15.0 μmol/l (SD = 5.3)*
PMID 21232119 · one of two readings recorded this
baseline serum MMA
n = 50
Mean (SD) | 0.43 μmol/l (SD = 0.25)* | 0.41 μmol/l (SD = 0.24)*
PMID 21232119 · one of two readings recorded this
baseline serum vitamin B12
n = 50
Mean (SD) | 164 pM/l (SD = 24) | 154 pM/l (SD = 20)
PMID 21232119 · one of two readings recorded this
hematocrit change vs placebo
no effect, p = 0.502, n = 50
Hematocrite (% red cells) | 39.6 (4.1); 26 | 40.1 (4.0); 26 | 39.7 (4.6); 24 | 39.4 (4.6); 22 | -0.4 (CI95% -1.7 to 0.8; p = 0.502) | 0.5 (CI95% -1.0 to 2.1; p = 0.475)
PMID 21232119 · one of two readings recorded this
hematocrit change vs placebo
no effect, p = 0.475, n = 48
Hematocrite (% red cells) | 39.6 (4.1); 26 | 40.1 (4.0); 26 | 39.7 (4.6); 24 | 39.4 (4.6); 22 | -0.4 (CI95% -1.7 to 0.8; p = 0.502) | 0.5 (CI95% -1.0 to 2.1; p = 0.475)
PMID 21232119 · one of two readings recorded this
mean corpuscular volume change vs placebo
no effect, p = 0.674, n = 50
MCV (fl) | 89.8 (6.9); 26 | 89.0 (7.0); 26 | 92.8 (7.0); 24 | 92.6 (7.6); 22 | -0.4 (CI95% -2.2 to 1.4; p = 0.674) | -0.1 (CI95% -2.3 to 2.2; p = 0.950)
PMID 21232119 · one of two readings recorded this
mean corpuscular volume change vs placebo
no effect, p = 0.95, n = 48
MCV (fl) | 89.8 (6.9); 26 | 89.0 (7.0); 26 | 92.8 (7.0); 24 | 92.6 (7.6); 22 | -0.4 (CI95% -2.2 to 1.4; p = 0.674) | -0.1 (CI95% -2.3 to 2.2; p = 0.950)
PMID 21232119 · one of two readings recorded this
Mini Mental State Examination change vs placebo
no effect, p = 0.432, n = 47
MMSE (score 0-30) | - | 27.8 (2.3); 26 | - | 28.1 (2.2); 21 | - | -0.4 (CI95% -1.3 to 0.6; p = 0.432)
PMID 21232119 · one of two readings recorded this
number needed to treat for improving MMA
the NNT for improving MMA serum concentration at one month was 2.6 patients (95% CI 1.7 to 9.4)
PMID 21232119 · one of two readings recorded this
proportion of patients with normal MMA at baseline
At baseline, 21.7% of patients had MMA levels that were considered normal (less than 0.26 μmol/l)
PMID 21232119 · one of two readings recorded this
relative improvement of homocysteine toward healthy mean
no effect, p = 0.844
Hcys (μmol/l) Reduction | 1.8% (CI95% -16.4:20.0; p = 0.844) | 6.7% (CI95% -11.3:24.7; p = 0.455)
PMID 21232119 · one of two readings recorded this
relative improvement of homocysteine toward healthy mean
no effect, p = 0.455
Hcys (μmol/l) Reduction | 1.8% (CI95% -16.4:20.0; p = 0.844) | 6.7% (CI95% -11.3:24.7; p = 0.455)
PMID 21232119 · one of two readings recorded this
relative improvement of MMA toward healthy mean
decreases, p = 0.001
MMA (μmol/l) Reduction | 48.7% (CI95% 29.0:68.3; p < 0.001) | 0.2% (CI95% -17.8:18.3; p = 0.979)
PMID 21232119 · one of two readings recorded this
relative improvement of MMA toward healthy mean
no effect, p = 0.979
MMA (μmol/l) Reduction | 48.7% (CI95% 29.0:68.3; p < 0.001) | 0.2% (CI95% -17.8:18.3; p = 0.979)
PMID 21232119 · one of two readings recorded this
relative improvement of serum cobalamin toward healthy mean
increases, p = 0.001
Serum cobalamin (pM/l) Increase | 26.9% (CI95% 13.9:39.8; p < 0.001) | 14.1% (CI95% -3.1:31.3; p = 0.105)
PMID 21232119 · one of two readings recorded this
relative improvement of serum cobalamin toward healthy mean
no effect, p = 0.105
Serum cobalamin (pM/l) Increase | 26.9% (CI95% 13.9:39.8; p < 0.001) | 14.1% (CI95% -3.1:31.3; p = 0.105)
PMID 21232119 · one of two readings recorded this
serum cobalamin change vs placebo
increases, p = 0.001, n = 49
Serum cobalamin (pM/l) | 263.4 (89.8); 25 | 202.6 (56.3); 23 | 154.5 (41.1); 24 | 162.9 (39.8); 23 | 101.6 (CI95% 60.1 to 143.2; p < 0.001) | 35.0 (CI95% 6.4 to 63.5; p = 0.018)
PMID 21232119 · one of two readings recorded this
serum cobalamin change vs placebo
increases, p = 0.018, n = 46
Serum cobalamin (pM/l) | 263.4 (89.8); 25 | 202.6 (56.3); 23 | 154.5 (41.1); 24 | 162.9 (39.8); 23 | 101.6 (CI95% 60.1 to 143.2; p < 0.001) | 35.0 (CI95% 6.4 to 63.5; p = 0.018)
PMID 21232119 · one of two readings recorded this
serum methylmalonic acid (GC-MS with isotopic dilution), change from baseline at one month, oral vitamin B12 1000 ug daily versus placebo; also serum B12 (radioimmunoassay) and total homocysteine (HPLC)
decreases, relative improvement toward healthy mean 48.7% (95% CI 29.0 to 68.3) over placebo
Not recorded as a finding: the supporting sentence never names the compound
At one month, patients undergoing vitamin B12 treatment decreased their mean deficit by 48.7% (95% CI 29.0 to 68.3) over placebo.
PMID 21232119 · one of two readings recorded this
serum MMA change vs placebo
decreases, p = 0.001, n = 45
MMA (μmol/l) | 0.23 (0.08); 22 | 0.41 (0.30); 19 | 0.37 (0.14); 23 | 0.35 (0.16); 22 | - 0.13 (CI95% -0.19 to -0.06; p < 0.001) | 0.03 (CI95% -0.12 to 0.17; p = 0.686)
PMID 21232119 · one of two readings recorded this
serum MMA change vs placebo
no effect, p = 0.686, n = 41
MMA (μmol/l) | 0.23 (0.08); 22 | 0.41 (0.30); 19 | 0.37 (0.14); 23 | 0.35 (0.16); 22 | - 0.13 (CI95% -0.19 to -0.06; p < 0.001) | 0.03 (CI95% -0.12 to 0.17; p = 0.686)
PMID 21232119 · one of two readings recorded this
serum MMA per-protocol analysis
no effect, p = 0.832
Per-protocol analysis also confirmed the absence of a difference in mean MMA concentrations between the placebo and treatment groups at four months (-0.02 μmol/l; 95% CI -0.16 to 0.13; p = 0.832)
PMID 21232119 · one of two readings recorded this
total homocysteine change vs placebo
no effect, p = 0.95, n = 45
Hcys (μmol/l) | 16.5 (6.1); 22 | 17.1 (7.5); 19 | 13.9 (4.3); 23 | 15.6 (5.8); 22 | 0.04 (CI95% -1.2 to 1.3; p = 0.950) | -1.0 (CI95% -4.0 to 2.0; p = 0.502)
PMID 21232119 · one of two readings recorded this
total homocysteine change vs placebo
no effect, p = 0.502, n = 41
Hcys (μmol/l) | 16.5 (6.1); 22 | 17.1 (7.5); 19 | 13.9 (4.3); 23 | 15.6 (5.8); 22 | 0.04 (CI95% -1.2 to 1.3; p = 0.950) | -1.0 (CI95% -4.0 to 2.0; p = 0.502)
PMID 21232119 · one of two readings recorded this
CD4+ cell percent < 25 by HAART status
p = 0.001, n = 199
Thirteen out of 40 children (32.5%) who were on HAART had CD4+ cell percent < 25 compared to 100/159 (63.5%) who were HAART naïve, p = 0.001
PMID 21600005 · one of two readings recorded this
CD4+ count
no effect, n = 214
6 months | 1039 (725 - 1358) | 1043 (704 - 1484)
PMID 21600005 · one of two readings recorded this
change in haemoglobin
n = 214
Change | 0.3 (-0.4 - 0.9) | 0.6 (-0.2 - 1.4)
PMID 21600005 · one of two readings recorded this
change in serum folate concentration
n = 214
Change | 8.0 (-0.3 - 17.1) | -0.6 (-3.5 - 5.8)
PMID 21600005 · one of two readings recorded this
change in serum vitamin B12 concentration
n = 214
Change | 90.5 (-0.8 - 203.5) | 10.0 (-73.8 - 83.8)
PMID 21600005 · one of two readings recorded this
haemoglobin
n = 214
6 months | 10.9 (9.4 - 11.7) | 10.6 (9.6 - 11.7)
PMID 21600005 · one of two readings recorded this
low folate association with age under 24 months
increases, n = 214
Age < 24 months | 70 | 27 (38.6) | 1.6 (1.1 - 2.4) | 2.2 (1.1 - 4.5)
PMID 21600005 · one of two readings recorded this
low folate association with haemoglobin < 11 g/dl
no effect, n = 214
Haemoglobin < 11 g/dl | 127 | 45 (35.4) | 1.8 (1.1 - 2.9) | 1.9 (0.9 - 4.6)
PMID 21600005 · one of two readings recorded this
low folate association with male sex
increases, n = 214
Male | 100 | 36 (36.0) | 1.6 (1.0 - 2.4) | 2.1 (1.1 - 4.0)
PMID 21600005 · one of two readings recorded this
low folate status at 6 months (MV vs MMS)
n = 214
Five children (11.4%) were supplemented with MMS and 39 (88.6%) MV; Odds ratio 10.8 (95% CI; 4.1 - 28.9)
PMID 21600005 · one of two readings recorded this
low vitamin B12 association with male sex
no effect, n = 214
Male | 100 | 33 (33.0) | 1.4 (0.9 - 2.1) | 1.6 (0.8 - 3.1)
PMID 21600005 · one of two readings recorded this
low vitamin B12 status at 6 months (MV vs MMS)
n = 214
The odds ratio was 4.5 (95% CI; 2.0 - 10.0)
PMID 21600005 · one of two readings recorded this
prevalence of low folate at baseline
n = 214
and 62 (29.0%) had low folate concentrations less than 13.4 nmol/L
PMID 21600005 · one of two readings recorded this
prevalence of low vitamin B12 at baseline
n = 214
Overall, 60 children (28.0%) had low vitamin B12 concentrations less than 221.0 pmol/L
PMID 21600005 · one of two readings recorded this
serum folate concentration
n = 214
6 months | 27.7 (21.1 - 33.4) | 16.5 (11.7 - 22.1)
PMID 21600005 · one of two readings recorded this
serum folate concentration
increases, p = 0.04, n = 19
The median (IQR) folate concentrations increased from 18.6 (13.8 - 23.9) to 25.0 (21.3 - 32.9) nmol/L, p = 0.040
PMID 21600005 · one of two readings recorded this
serum folate concentration
increases, p = 0.001, n = 104
Similarly folate concentrations increased from 17.3 (13.5 - 26.6) to 27.7 (21.1 - 33.4) nmol/L and this difference was also significant, p < 0.001
PMID 21600005 · one of two readings recorded this
serum vitamin B12 and folate concentrations at 6 months, electrochemiluminescence immunoassay; haemoglobin; CD4+ count
increases
Not recorded as a finding: the intervention held more than the compound
Low vitamin B12 and folate concentrations were more frequent in the MV supplemented group.
PMID 21600005 · one of two readings recorded this
serum vitamin B12 concentration
n = 214
6 months | 401.5 (264.3 - 518.8) | 288.5 (198.8 - 391.0)
PMID 21600005 · one of two readings recorded this
serum vitamin B12 concentration
increases, p = 0.002, n = 19
In this stratum the median (IQR) concentration of vitamin B12 in the MMS arm at baseline was 262.0 (215.0 - 342.0) compared to 453.0 (261.0 - 594.0) pmol/L at 6 months, p = 0.002
PMID 21600005 · one of two readings recorded this
serum vitamin B12 concentration
increases, n = 104
Following supplementation with multiple micronutrients (MMS) vitamin B12 concentrations increased from a median (IQR) of 285.5 (216.5 - 371.8) to 401.5 (264.3 - 518.8) pmol/L at 6 months
PMID 21600005 · one of two readings recorded this
Carotid intima-media thickness (IMT)
decreases, p = 0.05
carotid IMT (0.65±0.09mm, P<0.05)
PMID 22659999 · one of two readings recorded this
Carotid intima-media thickness (IMT)
decreases, p = 0.05
carotid IMT decreased (0.69±0.09mm to 0.67±0.09mm; p<0.05)
PMID 22659999 · one of two readings recorded this
HDL cholesterol
no effect
HDL-C (mmol/l) | l.4±0.3 | 1.4±0.4 | 1.4±0.3
PMID 22659999 · one of two readings recorded this
LDL cholesterol
no effect
LDL-C (mmol/l) | 2.5±0.8 | 2.4±0.7 | 2.4±0.8
PMID 22659999 · one of two readings recorded this
Glucose
no effect
Glucose (mmol/l) | 5.l±0.9 | 5.1±1.0 | 5.1±0.6
PMID 22659999 · one of two readings recorded this
Association of change in serum vitamin B-12 with change in FMD
increases, p = 0.02
On multivariate analysis, changes in vitamin B-12 (β=0.25; p=0.02) but not homocysteine level correlated with changes in FMD
PMID 22659999 · one of two readings recorded this
brachial artery flow-mediated dilation (FMD, ultrasound) and carotid intima-media thickness (ultrasound) in vegetarians with subnormal B12 status; oral vitamin B-12 500 ug/day (form not stated) versus placebo, 12-week double-blind crossover; also blood pressure, glucose, LDL-C, HDL-C reported as unchanged after B-12
increases, FMD 6.3 +/- 1.8% to 6.9 +/- 1.9%, p<0.0001 after vitamin B-12 but not after placebo (pre-to-post change within each crossover period; no between-treatment test reported in the Results)
Not recorded as a finding: the result compares a group with itself, not with a control
Brachial FMD significantly increased (6.3±1.8% to 6.9±1.9%; p<0.0001) and carotid IMT decreased (0.69±0.09mm to 0.67±0.09mm; p<0.05) after vitamin B-12 but not after placebo treatment.
PMID 22659999 · one of two readings recorded this
Brachial flow-mediated dilation (FMD)
increases, p = 0.001
Further improvement in brachial FMD (7.4±1.7%, P <0.001)
PMID 22659999 · one of two readings recorded this
Brachial flow-mediated dilation (FMD)
increases, p = 0.0001
Brachial FMD significantly increased (6.3±1.8% to 6.9±1.9%; p<0.0001)
PMID 22659999 · one of two readings recorded this
Diastolic blood pressure
no effect
Diastolic BP (mmHg) | 8l±l2 | 78±9 | 79±10
PMID 22659999 · one of two readings recorded this
Glyceryl trinitrate (GTN) response
no effect
GTN (%) | 17.1±2.7 | 18.2±2.0 | 18.8±2.1
PMID 22659999 · one of two readings recorded this
Plasma homocysteine
decreases
Homocysteine (µmol/l) | l6.7±ll.0 | 13.1±5.0 * | 11.3±6.0 **
PMID 22659999 · one of two readings recorded this
Reactive hyperemia
no effect
Reactive Hyperemia (%) | 883.9±97.l | 900.7±99.9 | 920.7±75.5
PMID 22659999 · one of two readings recorded this
resting supine systolic and diastolic blood pressure, mmHg (instrument not stated)
no effect
Not recorded as a finding: Only sentence is a within-period 'no significant changes' statement beside other endpoints, and the acquisition protocol is a resting supine reading with no device named, so it does not meet the office or unspecified-setting blood pressure node definitions cleanly
After vitamin B-12 supplementation, there was a significant increase in vitamin B-12 and fall in homocysteine levels but no significant changes in blood pressure, serum glucose or LDL- cholesterol.
PMID 22659999 · one of two readings recorded this
Serum folate
no effect
Folate (nmol/l) | 39.4±l0.4 | 39.2±14.2 | 40.0±12.3
PMID 22659999 · one of two readings recorded this
serum glucose after a 14-h fast and LDL-cholesterol, assay not stated
no effect
Not recorded as a finding: Same sentence as the blood pressure null: a within-period statement after B-12 only, agentless for the placebo arm, and the glucose assay and LDL derivation are not stated
After vitamin B-12 supplementation, there was a significant increase in vitamin B-12 and fall in homocysteine levels but no significant changes in blood pressure, serum glucose or LDL- cholesterol.
PMID 22659999 · one of two readings recorded this
Serum vitamin B-12
increases
B-l2 (pmol/l) | l34.0±l25.6 | 185.7±145.4 * | 379.6±206.2#
PMID 22659999 · one of two readings recorded this
Systolic blood pressure
no effect
Systolic BP (mmHg) | l22±l4 | 117±13 | 117±16
PMID 22659999 · one of two readings recorded this
complete early viral response (undetectable HCV-RNA at 12 weeks)
increases, p = 0.03
the rates of complete early viral response (p=0.03)
PMID 22810757 · one of two readings recorded this
end-of-treatment viral response
increases, p = 0.03
end-of-treatment viral response (p=0.03)
PMID 22810757 · one of two readings recorded this
IL-28B genotype distribution
no effect
Distribution of genotype IL-28B did not differ between the two groups
PMID 22810757 · one of two readings recorded this
rapid viral response (undetectable HCV-RNA at 4 weeks)
no effect
Overall, rapid viral response did not differ between the two groups
PMID 22810757 · one of two readings recorded this
sustained viral response (SVR)
increases, p = 0.001
and SVR (p=0.001)
PMID 22810757 · one of two readings recorded this
sustained viral response (undetectable serum HCV-RNA 24 weeks after completing treatment) in chronic hepatitis C, pegylated interferon alpha plus ribavirin with or without vitamin B12
increases, p = 0.001
Not recorded as a finding: this platform holds no node for the endpoint
Overall, rapid viral response did not differ between the two groups, whereas the rates of complete early viral response (p=0.03), end-of-treatment viral response (p=0.03) and SVR (p=0.001) were significantly higher in SOC+B12 patients than in SOC patients.
PMID 22810757 · one of two readings recorded this
sustained viral response (undetectable serum HCV-RNA 24 weeks after completing treatment), SOC plus B12 versus SOC alone
increases, SVR rate significantly higher in SOC+B12 than SOC, p = 0.001
Not recorded as a finding: this platform holds no node for the endpoint
Overall, rapid viral response did not differ between the two groups, whereas the rates of complete early viral response (p=0.03), end-of-treatment viral response (p=0.03) and SVR (p=0.001) were significantly higher in SOC+B12 patients than in SOC patients.
PMID 22810757 · one of two readings recorded this
SVR, multivariate analysis, easy-to-treat HCV genotypes
increases, p = 0.001
easy-to-treat HCV genotypes (OR=9.00; 95% CI 2.5 to 37.5; p=0.001)
PMID 22810757 · one of two readings recorded this
SVR, multivariate analysis, vitamin B12 supplementation
increases, p = 0.002
vitamin B12 supplementation (OR=6.9; 95% CI 2.0 to 23.6; p=0.002)
PMID 22810757 · one of two readings recorded this
SVR rate in carriers of a difficult-to-treat genotype
increases, p = 0.002
the SVR rate was also significantly higher in carriers of a difficult-to-treat genotype (p=0.002)
PMID 22810757 · one of two readings recorded this
SVR rate in patients with a high baseline viral load
increases, p = 0.002
and in patients with a high baseline viral load (p=0.002)
PMID 22810757 · one of two readings recorded this
equivocal hematologic response
n = 192
Another 5 patients had equivocal hematologic responses
PMID 23262189 · one of two readings recorded this
objectively documented hematologic response (MCV decrease by ≥5 fL with stable or improved hemoglobin)
n = 192
Only 12 patients had objectively documented hematologic responses: decrease of mean corpuscular volume by ≥5 fL with stable or improved hemoglobin
PMID 23262189 · one of two readings recorded this
objectively documented hematologic response (mean corpuscular volume decrease of at least 5 fL with stable or improved hemoglobin) after intramuscular vitamin B12 injections, retrospective chart review
18 of 192 patients (9.4%) had data supportive of a clinical response, n = 192
Not recorded as a finding: this platform holds no node for the endpoint
Thus, only 18 (9.4%) of 192 patients had data supportive of a clinical response.
PMID 23262189 · one of two readings recorded this
patients with data supportive of a clinical response
n = 192
Thus, only 18 (9.4%) of 192 patients had data supportive of a clinical response
PMID 23262189 · one of two readings recorded this
proportion of patients with a documented hematologic response (mean corpuscular volume decrease of at least 5 fL with stable or improved hemoglobin) after intramuscular vitamin B12 injections, retrospective chart review of 192 patients, no control arm
18 of 192 patients (9.4%) with data supportive of a clinical response, n = 192
Not recorded as a finding: this platform holds no node for the endpoint
Thus, only 18 (9.4%) of 192 patients had data supportive of a clinical response.
PMID 23262189 · one of two readings recorded this
energy intake
AfAm men (2,194 kcal/day) and JpAm women (1,808 kcal/day) reported the lowest energy intake
PMID 23398393 · one of two readings recorded this
energy intake
AfAm men (2,194 kcal/day) and JpAm women (1,808 kcal/day) reported the lowest energy intake
PMID 23398393 · one of two readings recorded this
energy intake
NH had the highest energy intakes for men (2,760 kcal/day) and women (2,370 kcal/day)
PMID 23398393 · one of two readings recorded this
energy intake
NH had the highest energy intakes for men (2,760 kcal/day) and women (2,370 kcal/day)
PMID 23398393 · one of two readings recorded this
mean BMI
NH men (28.5 kg/m2) and AfAm women (28.4 kg/m2) had the highest mean BMI
PMID 23398393 · one of two readings recorded this
mean BMI
NH men (28.5 kg/m2) and AfAm women (28.4 kg/m2) had the highest mean BMI
PMID 23398393 · one of two readings recorded this
baseline RBC folate vs 16-week SANS change, lowest tertile
increases, p = 0.04
in the lowest tertile (r=.43, p=.04) but not the middle (r=.29, p=.20) or upper (r=.23, p=.29) tertiles
PMID 23467813 · one of two readings recorded this
baseline RBC folate vs 16-week SANS change, middle tertile
no effect, p = 0.2
in the lowest tertile (r=.43, p=.04) but not the middle (r=.29, p=.20) or upper (r=.23, p=.29) tertiles
PMID 23467813 · one of two readings recorded this
baseline RBC folate vs 16-week SANS change, upper tertile
no effect, p = 0.29
in the lowest tertile (r=.43, p=.04) but not the middle (r=.29, p=.20) or upper (r=.23, p=.29) tertiles
PMID 23467813 · one of two readings recorded this
baseline RBC folate vs baseline SANS, lowest tertile
decreases, p = 0.01
Baseline RBC folate correlated inversely with baseline SANS in the lowest tertile (r= -.39, p=.01), but not in the middle (r= -.27, p=.09) or upper (r= -.16, p=.35) tertiles
PMID 23467813 · one of two readings recorded this
baseline RBC folate vs baseline SANS, middle tertile
no effect, p = 0.09
Baseline RBC folate correlated inversely with baseline SANS in the lowest tertile (r= -.39, p=.01), but not in the middle (r= -.27, p=.09) or upper (r= -.16, p=.35) tertiles
PMID 23467813 · one of two readings recorded this
baseline RBC folate vs baseline SANS, upper tertile
no effect, p = 0.35
Baseline RBC folate correlated inversely with baseline SANS in the lowest tertile (r= -.39, p=.01), but not in the middle (r= -.27, p=.09) or upper (r= -.16, p=.35) tertiles
PMID 23467813 · one of two readings recorded this
change in negative symptoms (SANS), folate plus B12 vs placebo
decreases, p = 0.02, n = 120
the main effect of treatment over time became significant (group difference -0.33 per week; 95% CI, -0.62 to -0.05; p=.02)
PMID 23467813 · one of two readings recorded this
change in negative symptoms (SANS), folate plus B12 vs placebo
no effect, p = 0.15, n = 135
the difference between folate and placebo groups did not reach significance (-0.21 per week; 95% CI, -0.49 to 0.07; p=.15)
PMID 23467813 · one of two readings recorded this
change in negative symptoms (SANS), folate plus B12 vs placebo
decreases, p = 0.005, n = 120
with active treatment conferring a benefit over placebo in the T/T group (treatment group difference -0.59 per week; 95% CI, -0.99 to -0.18; p=.005)
PMID 23467813 · one of two readings recorded this
change in negative symptoms (SANS), folate plus B12 vs placebo
no effect, p = 0.64, n = 120
among C allele carriers (treatment group difference +0.09 per week; 95% CI, -0.29 to 0.47; p=.64)
PMID 23467813 · one of two readings recorded this
change in negative symptoms (SANS)
decreases, p = 0.04, n = 120
a significant decline in negative symptoms in the active treatment group (-0.17 per week; 95% CI, -0.34 to -0.01; p=.04)
PMID 23467813 · one of two readings recorded this
change in negative symptoms (SANS)
decreases, p = 0.02, n = 135
Patients who received folate plus B12 exhibited a significant decline in negative symptoms (-0.19 change in SANS per week; 95% CI, -0.35 to -0.03; p=.02)
PMID 23467813 · one of two readings recorded this
change in negative symptoms (SANS)
no effect, p = 0.18, n = 120
the placebo group (+0.16 per week; 95% CI, -0.07 to 0.39; p=.18)
PMID 23467813 · one of two readings recorded this
change in negative symptoms (SANS)
no effect, n = 135
those who received placebo did not change (+0.02 per week; 95% CI, -0.21 to 0.24; p=88)
PMID 23467813 · one of two readings recorded this
depression scores
no effect, n = 135
No significant effects of treatment were seen for depression scores
PMID 23467813 · one of two readings recorded this
dietary folate and B12 intake, between-group difference
no effect, p = 0.24
Dietary folate and B12 intake did not differ significantly between treatment groups at baseline, week 8, or week 16 (p>.24)
PMID 23467813 · one of two readings recorded this
negative symptoms of schizophrenia, Scale for the Assessment of Negative Symptoms (SANS) change per week; PANSS positive and total scores; Calgary Depression Rating Scale
no effect, -0.21 per week; 95% CI, -0.49 to 0.07, p = 0.15
Not recorded as a finding: the intervention held more than the compound
Patients who received folate plus B12 exhibited a significant decline in negative symptoms (-0.19 change in SANS per week; 95% CI, -0.35 to -0.03; p=.02) and those who received placebo did not change (+0.02 per week; 95% CI, -0.21 to 0.24; p=88), although the difference between folate and placebo groups did not reach significance (-0.21 per week; 95% CI, -0.49 to 0.07; p=.15).
PMID 23467813 · one of two readings recorded this